Newman Dignan & Sheerar Inc. Decreases Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Newman Dignan & Sheerar Inc. trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 16.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 312 shares of the biopharmaceutical company’s stock after selling 60 shares during the quarter. Newman Dignan & Sheerar Inc.’s holdings in Regeneron Pharmaceuticals were worth $222,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the company. Trust Co. of Vermont increased its stake in shares of Regeneron Pharmaceuticals by 8.3% in the third quarter. Trust Co. of Vermont now owns 157 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 12 shares during the period. Nvwm LLC increased its stake in shares of Regeneron Pharmaceuticals by 1.4% in the third quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company’s stock worth $1,039,000 after buying an additional 14 shares during the period. Moss Adams Wealth Advisors LLC increased its stake in shares of Regeneron Pharmaceuticals by 3.6% in the third quarter. Moss Adams Wealth Advisors LLC now owns 434 shares of the biopharmaceutical company’s stock worth $456,000 after buying an additional 15 shares during the period. Westhampton Capital LLC increased its stake in shares of Regeneron Pharmaceuticals by 1.7% in the third quarter. Westhampton Capital LLC now owns 893 shares of the biopharmaceutical company’s stock worth $939,000 after buying an additional 15 shares during the period. Finally, Howe & Rusling Inc. increased its stake in shares of Regeneron Pharmaceuticals by 3.4% in the third quarter. Howe & Rusling Inc. now owns 462 shares of the biopharmaceutical company’s stock worth $486,000 after buying an additional 15 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently commented on REGN. Bernstein Bank decreased their target price on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Oppenheimer cut their price target on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Citigroup cut their price target on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Royal Bank of Canada cut their price target on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $673.60 on Friday. The stock has a market cap of $74.02 billion, a price-to-earnings ratio of 17.60, a PEG ratio of 2.38 and a beta of 0.08. The firm’s 50-day moving average is $706.92 and its 200 day moving average is $897.42. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 4.46.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $11.86 EPS. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 36.67 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.52%. The ex-dividend date is Thursday, February 20th.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.